Stage-related outcome for thymic epithelial tumours.
Iterative surgery
Masaoka staging system
Oncological outcome
Surgery
Thymic carcinoma
Thymic epithelial tumours
Thymoma
Journal
BMC surgery
ISSN: 1471-2482
Titre abrégé: BMC Surg
Pays: England
ID NLM: 100968567
Informations de publication
Date de publication:
24 Apr 2019
24 Apr 2019
Historique:
received:
26
09
2018
accepted:
29
10
2018
entrez:
11
5
2019
pubmed:
11
5
2019
medline:
3
7
2019
Statut:
epublish
Résumé
Thymic epithelial tumours (TETs) are characterized by a wide variety of biological behaviors. Radical resection and stage are strong prognostic factors. Aim of this study is to review our Single Center Experience. One hundred and seventy-seven patients observed in the period from January 2000 to December 2016 were included in the study. Data regarding clinicopathologic features, treatment, and survival were collected. Stage-related clinical standpoints and therapeutic options were also evaluated. Non-surgical treatment was primarily performed in 15 (8.47%), unresectable disease was intraoperatively found in 12 cases (7.4%). The analysis of 150 patients undergoing curative surgery revealed 70 stage I TET (46.66%), 49 stage II (32.66%), 19 stage III (12.66%), 6 stage IVa (4%) and 6 stage IVb (4%) at the first hospital admission. Histology identified 12 A thymoma (8%), 38 AB (25.33%), 24 B1 (16%), 50 B2 (33.33%), 19 B3 (12.66%) and 7 carcinomas (4.66%). The mean follow up time was 84.14 months (sd = 61.68 months). Disease relapse occurred in 13 patients (8.78%) at a mean period of 78.85 months (sd = 60.87 months) after surgery. Exitus due to thymoma happened in 6 cases (4.05%) after a mean survival of 56.02 months (sd = 25.17 months). The 5-year overall survival rate was 0.94 (95%CI 0.88-0.97) and the 5-year disease-free survival rate was 0.90 (95%CI 0.83-0.94). The 5-year overall survival rates were 96.1% (95% CI, 89.9-98.5%) for the early stages and 87.4% (95% CI, 65.6-95.8%) for the advanced stages (p = 0.670). The 5-year disease-free survival rates resulted being 98.8% (95% CI, 92.3-99.8%) for the early stages and 59.8% (95% CI, 37.8-76.2%) for the advanced stages (p < 0.001). Advanced stage TETs are characterized by higher mortality and recurrence rates. Although technically demanding, surgery, as part of multimodality therapy, could prolong survival. Iterative surgical treatment of recurrences is a viable option for selected patients. The study was approved by the Institutional Review Board of Perugia and Terni University Hospitals [Code T1003] and was retrospectively registered.
Sections du résumé
BACKGROUND
BACKGROUND
Thymic epithelial tumours (TETs) are characterized by a wide variety of biological behaviors. Radical resection and stage are strong prognostic factors. Aim of this study is to review our Single Center Experience.
METHODS
METHODS
One hundred and seventy-seven patients observed in the period from January 2000 to December 2016 were included in the study. Data regarding clinicopathologic features, treatment, and survival were collected. Stage-related clinical standpoints and therapeutic options were also evaluated.
RESULTS
RESULTS
Non-surgical treatment was primarily performed in 15 (8.47%), unresectable disease was intraoperatively found in 12 cases (7.4%). The analysis of 150 patients undergoing curative surgery revealed 70 stage I TET (46.66%), 49 stage II (32.66%), 19 stage III (12.66%), 6 stage IVa (4%) and 6 stage IVb (4%) at the first hospital admission. Histology identified 12 A thymoma (8%), 38 AB (25.33%), 24 B1 (16%), 50 B2 (33.33%), 19 B3 (12.66%) and 7 carcinomas (4.66%). The mean follow up time was 84.14 months (sd = 61.68 months). Disease relapse occurred in 13 patients (8.78%) at a mean period of 78.85 months (sd = 60.87 months) after surgery. Exitus due to thymoma happened in 6 cases (4.05%) after a mean survival of 56.02 months (sd = 25.17 months). The 5-year overall survival rate was 0.94 (95%CI 0.88-0.97) and the 5-year disease-free survival rate was 0.90 (95%CI 0.83-0.94). The 5-year overall survival rates were 96.1% (95% CI, 89.9-98.5%) for the early stages and 87.4% (95% CI, 65.6-95.8%) for the advanced stages (p = 0.670). The 5-year disease-free survival rates resulted being 98.8% (95% CI, 92.3-99.8%) for the early stages and 59.8% (95% CI, 37.8-76.2%) for the advanced stages (p < 0.001).
CONCLUSIONS
CONCLUSIONS
Advanced stage TETs are characterized by higher mortality and recurrence rates. Although technically demanding, surgery, as part of multimodality therapy, could prolong survival. Iterative surgical treatment of recurrences is a viable option for selected patients.
TRIAL REGISTRATION
BACKGROUND
The study was approved by the Institutional Review Board of Perugia and Terni University Hospitals [Code T1003] and was retrospectively registered.
Identifiants
pubmed: 31074388
doi: 10.1186/s12893-018-0434-z
pii: 10.1186/s12893-018-0434-z
pmc: PMC7402578
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
114Références
J Vis Surg. 2017 Jul 27;3:96
pubmed: 29078658
Thorac Cardiovasc Surg. 2014 Mar;62(2):161-8
pubmed: 23775415
J Vis Surg. 2017 May 11;3:68
pubmed: 29078631
Curr Treat Options Oncol. 2008 Dec;9(4-6):259-68
pubmed: 19169830
Ann Thorac Surg. 2003 Dec;76(6):1859-64; discussion 1864-5
pubmed: 14667600
Ann Thorac Surg. 2007 Apr;83(4):1526-8
pubmed: 17383375
Surg Today. 2007;37(3):192-6
pubmed: 17342355
World J Surg. 2013 Dec;37(12):2740-6
pubmed: 24154574
Interact Cardiovasc Thorac Surg. 2010 Nov;11(5):696-7
pubmed: 20719905
Contrast Media Mol Imaging. 2017 Jan 10;2017:9307292
pubmed: 29097942
J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S344-7
pubmed: 20859130
Eur J Cardiothorac Surg. 2015 Mar;47(3):567-72
pubmed: 24842578
Ann Thorac Surg. 2017 Feb;103(2):422-431
pubmed: 27825684
J Thorac Cardiovasc Surg. 2009 Jul;138(1):26-31
pubmed: 19577051
J Thorac Imaging. 2013 Mar;28(2):69-80; quiz 81-3
pubmed: 23422781
J Thorac Oncol. 2015 Oct;10(10):1383-95
pubmed: 26295375
J Thorac Oncol. 2015 Feb;10(2):367-72
pubmed: 25616178
J Thorac Oncol. 2014 Jul;9(7):1023-1030
pubmed: 24926547
J Thorac Oncol. 2011 Jul;6(7 Suppl 3):S1698-704
pubmed: 21847050
Cancer Treat Rev. 2014 May;40(4):495-506
pubmed: 24355362
J Thorac Dis. 2017 Oct;9(10):3817-3824
pubmed: 29268390
J Thorac Oncol. 2014 Oct;9(10):1573-8
pubmed: 25521402
Gen Thorac Cardiovasc Surg. 2014 Aug;62(8):468-74
pubmed: 24913632
J Thorac Oncol. 2011 Jul;6(7 Suppl 3):S1739-42
pubmed: 21847056
Clin Radiol. 2016 Oct;71(10):1010-7
pubmed: 27267746
J Thorac Cardiovasc Surg. 2005 Nov;130(5):1413-21
pubmed: 16256797
Radiographics. 2017 May-Jun;37(3):758-776
pubmed: 28493800
Cancer. 1981 Dec 1;48(11):2485-92
pubmed: 7296496
Thorac Cardiovasc Surg. 2012 Mar;60(2):175-6
pubmed: 21766278
Chin Med J (Engl). 2013;126(11):2186-91
pubmed: 23769581
J Thorac Cardiovasc Surg. 2014 May;147(5):1599-603
pubmed: 24290709
Eur J Cardiothorac Surg. 2016 Jun;49(6):1545-52
pubmed: 26670806